Christine Benz, Morningstar’s director of personal finance and retirement planning, recommends taking a preemptive approach ...

GE Vernova shares are up nearly 50% year to date, handily outperforming the broad market, as outer-year financial ...

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes ...

Gains in megacap tech stocks lifted U.S. indexes, overcoming headwinds from another flare-up in trade tensions. The S&P 500 ticked up 0.4%. China's Manufacturing Activity Tumbles Into Contraction as ...

SYDNEY--The global trade war being pursued by the Trump administration will ultimately smash demand and growth, more so than creating added inflation risks, said Sarah Hunter, chief economist at the ...

Boeing Co.'s stock is poised to gain about 25% within the next year, as the aerospace and defense giant has emerged as a favorite "trade tool" for the Trump administration and has made progress under ...

Furthermore, Kyocera has been gradually improving its shareholder return policy. Kyocera raised its dividend payout ratio target from 30% to 40% in fiscal 2016 and to 50% in fiscal 2019. Overall, we ...

SYDNEY--The Reserve Bank of Australia's monetary policy board seriously debated an emergency interest rate cut of 50 basis points in May due to growing uncertainty around the global growth outlook and ...

Gains in megacap tech stocks lifted U.S. indexes, overcoming headwinds from another flare-up in trade tensions. The S&P 500 ticked up 0.4%. U.S. Proposes Lifting Oil and Gas Development Curbs at ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.

Gains in megacap tech stocks lifted U.S. indexes, overcoming headwinds from another flare-up in trade tensions. The S&P 500 ticked up 0.4%. The Chinese Commerce Ministry said Washington had "seriously ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.